These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1960767)

  • 1. Combined naloxone/methadone preparations for opiate substitution therapy.
    Loimer N; Presslich O; Grünberger J; Linzmayer L
    J Subst Abuse Treat; 1991; 8(3):157-60. PubMed ID: 1960767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time course of naloxone-precipitated withdrawal after acute methadone exposure in humans.
    Stitzer ML; Wright C; Bigelow GE; June HL; Felch LJ
    Drug Alcohol Depend; 1991 Dec; 29(1):39-46. PubMed ID: 1665778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of opiate withdrawal-like symptoms by cocaine abuse during methadone and buprenorphine maintenance.
    Stine SM; Kosten TR
    Am J Drug Alcohol Abuse; 1994 Nov; 20(4):445-58. PubMed ID: 7832179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naloxone-induced withdrawal in patients with buprenorphine dependence.
    Nigam AK; Srivastava RP; Saxena S; Chavan BS; Sundaram KR
    Addiction; 1994 Mar; 89(3):317-20. PubMed ID: 8173501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial methadone dose in treating opiate addiction.
    Wang RI; Kochar C; Hasegawa AT; Roh BL
    Int J Addict; 1982 Feb; 17(2):357-63. PubMed ID: 7076369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buprenorphine and naloxone interactions in methadone maintenance patients.
    Mendelson J; Jones RT; Welm S; Brown J; Batki SL
    Biol Psychiatry; 1997 Jun; 41(11):1095-101. PubMed ID: 9146820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.
    Altice FL; Friedland GH; Cooney EL
    AIDS; 1999 May; 13(8):957-62. PubMed ID: 10371177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid overdose prevention with intranasal naloxone among people who take methadone.
    Walley AY; Doe-Simkins M; Quinn E; Pierce C; Xuan Z; Ozonoff A
    J Subst Abuse Treat; 2013 Feb; 44(2):241-7. PubMed ID: 22980450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation.
    Degenhardt L; Larance BK; Bell JR; Winstock AR; Lintzeris N; Ali RL; Scheuer N; Mattick RP
    Med J Aust; 2009 Aug; 191(3):161-5. PubMed ID: 19645647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical mismanagement in public methadone programs.
    Blansfield HN
    Conn Med; 1994 Mar; 58(3):161-4. PubMed ID: 8039380
    [No Abstract]   [Full Text] [Related]  

  • 11. Use predicts treatment outcome, not opiate dependence or withdrawal.
    Kosten TA; Bianchi MS; Kosten TR
    NIDA Res Monogr; 1989; 95():459-60. PubMed ID: 2641030
    [No Abstract]   [Full Text] [Related]  

  • 12. Rifampin-induced methadone withdrawal in AIDS.
    Holmes VF
    J Clin Psychopharmacol; 1990 Dec; 10(6):443-4. PubMed ID: 2286719
    [No Abstract]   [Full Text] [Related]  

  • 13. Methadone and naloxone in combination (Naldone) for the treatment of heroin addicts.
    Caruso FS; Gordon M; Pachter IJ
    Proc Natl Conf Methadone Treat; 1973; 2():1336-41. PubMed ID: 4215978
    [No Abstract]   [Full Text] [Related]  

  • 14. Oxycodone/naloxone preparation can cause acute withdrawal symptoms when misused parenterally or taken orally.
    Wong A; Macleod D; Robinson J; Koutsogiannis Z; Graudins A; Greene SL
    Clin Toxicol (Phila); 2015; 53(8):815-8. PubMed ID: 26109423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evolution and update of detoxification techniques for opiate addicts].
    Yui K
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2000 Oct; 20(4):175-7. PubMed ID: 11215403
    [No Abstract]   [Full Text] [Related]  

  • 16. Technique for greatly shortening the transition from methadone to naltrexone maintenance of patients addicted to opiates.
    Loimer N; Lenz K; Schmid R; Presslich O
    Am J Psychiatry; 1991 Jul; 148(7):933-5. PubMed ID: 2053636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for maintenance pharmacotherapy of opiate dependence.
    Kreek MJ
    Res Publ Assoc Res Nerv Ment Dis; 1992; 70():205-30. PubMed ID: 1346939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medically assisted recovery from opiate dependence within the context of the UK drug strategy: methadone and Suboxone (buprenorphine-naloxone) patients compared.
    McKeganey N; Russell C; Cockayne L
    J Subst Abuse Treat; 2013 Jan; 44(1):97-102. PubMed ID: 22703715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of health-related quality of life of opiate users at entry to low-threshold methadone programs.
    Millson P; Challacombe L; Villeneuve PJ; Strike CJ; Fischer B; Myers T; Shore R; Hopkins S
    Eur Addict Res; 2006; 12(2):74-82. PubMed ID: 16543742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia.
    Piralishvili G; Otiashvili D; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
    J Subst Abuse Treat; 2015 Mar; 50():32-7. PubMed ID: 25456093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.